KR101873682B1 - Novel Lactobacillus acidophilus KNU-02 having immune enhancing activity and use thereof - Google Patents

Abstract

A novel Lactobacillus acidophilus KNU-02 strain of the present invention increase the weight of pig, decreases viremia, and has an effect of mitigate lung lesion such that the present invention can be used as a microbial agent for enhancing immune systems of stocks. In addition, the present invention can be effectively used in various conditions such as oral freeze drying powder agent or an animal feed additive.

Description

Novel Lactobacillus acidophilus KNU-02 strain having immunity enhancing effect and its use (Novel Lactobacillus acidophilus KNU-02 having immune enhancing activity and use thereof)

The present invention relates to a novel Lactobacillus acidophilus KNU-02 strain having an immune enhancing effect for increasing the body weight of pigs, reducing blood virus concentration, alleviating lung lesions, and a livestock immune enhancer, To a freeze-dried powder preparation for oral use and a feed additive.

Livestock has been known as a useful animal that has been refined by humans for generations. These livestock have helped farming but have also been used as useful food resources, of which pigs are an important food resource and are still being consumed. Pigs are divided into piglets, breeding pigeons, finishing pigs, and sows (sows) by growth period. The pigs mean pigs and pigs that grow up after the piglets are called breeding pigs. Growing pigs are called pens. Weaning period is the period when weaning is the reason for weaning pigs. In particular, weaning pigs are one of the most important periods in the breeding of pigs because they are the time to form pigs immunity by milking.

Recently, pandemic influenza has been increasingly affected by swine viral diseases, such as those caused by the infectious diseases caused by viruses. In particular, the respiratory system of animals in which gas exchange occurs is the most active place of innate immunity since it is easily exposed to external pathogens. Viruses causing respiratory diseases are very diverse, and the infection site, host range, . In addition, most viral respiratory diseases are characterized by a very fast propagation rate, which makes it difficult to prevent and cure viral diseases in pigs.

In addition, viral diseases have a great influence on the breeding and market supply of pigs. Efforts to control viral infections, such as blocking and vaccination of preventive vaccines, have been actively conducted to solve these problems. However, genetic variation of the virus, incomplete efficacy of the vaccine, and lack of antiviral agents for use in animals are causing difficulties.

On the other hand, since the vaccine is a diluted pathogen made to artificially induce the antibody corresponding to the virus, diseases can be induced by the vaccine, the feebleness of the livestock is weakened, , And there are various side effects such as shock and shock after vaccination. Recently, the livestock immune enhancer has been attracting much attention in order to solve these side effects and meet the demand for environmentally friendly livestock industry.

The livestock immunity enhancer is a substance that enhances the normal or decreased immunity of livestock. Recently, the probiotics (probiotics) have been used as an immunity enhancer by paying attention to enhancement of bio-defense against microbial infection. Probiotics was defined by R. Fuller in 1989 as "Probiotics that have beneficial effects on host animals due to improved intestinal microflora of host animals". Examples of the strain used as a probiotic agent include fungi such as Lactobacillus, Enterococcus, Bifidobacterium, and Bacillus, yeasts including Saccharomyces, and fungi including Aspergillus. Probiotics are classified as Generally Recognized As Safe (GRAS), do not have toxic genes for humans and animals, and do not produce pathogenic substances. And microorganisms whose improvement efficacy against livestock productivity has been confirmed. Characteristics of probiotics are non-pathogenic, easy in vitro propagation, fast growing in vivo, acidic, and biliary. In addition, the activity by the feed ingredient should not be inhibited, and the effect should be maintained at room temperature.

Therefore, a recent study (Korean Patent Laid-Open No. 10-2008-0075389) for inhibiting the growth of pathogenic or harmful microorganisms by mixing lactic acid bacteria with the feed of livestock has been under way yet.

Accordingly, the present inventors have isolated and identified a novel strain having an effect as a poultry immunity enhancer in the feces of healthy pigs. The strain is safe for oral administration as a GRAS strain, and can be usefully used as a feed additive.

Accordingly, the present inventors have made intensive efforts to increase the breeding of pigs by alleviating the problems caused by the vaccine and enhancing the immunity. As a result, the Lactobacillus acidophilus strain KNU-02 has been shown to increase the daily gain of pigs, ) Reduction effect and an effect on alleviation of lung lesion, and based on this, the present invention has been completed.

Accordingly, an object of the present invention is to provide a novel Lactobacillus acidophilus strain KNU-02 (Accession No. KCTC13233BP) having an immunostimulating effect.

In addition, another object of the present invention is to provide a method for producing Lactobacillus acidophilus KNU-02, which is selected from the group consisting of Lactobacillus acidophilus strain KNU-02, a culture of the strain, a concentrate of the culture, a dried product of the culture, A lyophilized immune enhancer, an oral lyophilized powder preparation, and a feed additive comprising at least one active ingredient.

However, the technical problem to be solved by the present invention is not limited to the above-mentioned problems, and other matters not mentioned can be clearly understood by those skilled in the art from the following description.

In order to achieve the object of the present invention, the present invention provides a novel Lactobacillus acidophilus KNU-02 strain (Accession No. KCTC13233BP) having an immunostimulating effect.

In one embodiment of the present invention, the strain is characterized in that it comprises a gene (rDNA) base sequence encoding 16S rRNA of SEQ ID NO: 1.

The present invention also relates to a method for producing Lactobacillus acidophilus KNU-02 strain (Accession No. KCTC13233BP), a culture of the strain, a concentrate of the culture, a dried product of the culture and a combination thereof Or a pharmaceutically acceptable salt thereof as an active ingredient.

In one embodiment of the present invention, the livestock is a pig.

In another embodiment of the present invention, the pig is characterized by being a progeny.

In another embodiment of the present invention, the livestock enhancer is characterized in that it increases the daily gain rate.

In another embodiment of the present invention, the livestock enhancer is characterized by reducing viremia in the blood.

In still another embodiment of the present invention, the livestock enhancer is characterized by having a mitigation effect on lung lesions.

The present invention also relates to a method for producing a microorganism belonging to the group consisting of the Lactobacillus acidophilus KNU-02 strain (Accession No. KCTC13233BP), a culture of the strain, a concentrate of the culture, a dried product of the culture, Wherein the freeze-dried powder preparation for oral use contains at least one selected as an active ingredient.

In addition, the present invention provides a method for producing Lactobacillus acidophilus strain KNU-02 (strain No. KCTC13233BP), a culture of the strain, a concentrate of the culture, a dried product of the culture, A feed additive containing at least one selected as an active ingredient is provided.

The novel Lactobacillus acidophilus KNU-02 strain according to the present invention has an effect of increasing the daily rate of growth of pigs, decreasing viremia in the blood, alleviating lung lesions, Can be used as a microbial preparation for enhancing, and can be effectively used under various conditions such as a freeze-dried powder preparation for oral use or a feed additive using the same.

1 is a nucleotide sequence of a gene (rDNA) encoding 16S rRNA of Lactobacillus acidophilus strain KNU-02 of the present invention.
FIG. 2 is a phylogenetic diagram showing the nucleotide sequence of the gene (rDNA) encoding 16S rRNA of Lactobacillus acidophilus strain KNU-02 of the present invention in comparison with known strains.
FIG. 3 is a graph showing the effect of the Lactobacillus acidophilus KNU-02 strain of the present invention on the daily growth rate of the weaning piglets.
4 is a graph showing the effect of the Lactobacillus acidophilus strain KNU-02 according to the present invention on the viremia reduction effect of the piglets of the present invention.
FIG. 5 is a graph showing the effect of the Lactobacillus acidophilus KNU-02 strain of the present invention on pulmonary lesion reduction of the weaned piglets.
Fig. 6 shows a powder obtained by lyophilizing Lactobacillus acidophilus strain KNU-02.

The present inventors confirmed the effect of the novel Lactobacillus acidophilus KNU-02 strain on the increase of swine growth rate, decrease of viremia in blood, and mitigation of lung lesion.

Hereinafter, the present invention will be described in detail.

The present invention provides a novel Lactobacillus acidophilus strain KNU-02 (Accession No. KCTC13233BP) having an immunostimulating effect.

In the present invention, Lactobacillus acidophilus KNU-02 strain comprises a gene (rDNA) sequence encoding 16S rRNA of SEQ ID NO: 1, and the Lactobacillus acidophilus acidophilus acidophilus 99% homology to Lactobacillus acidophilus JCM7711, and 1% homology between both strains was recognized and proved to be a novel strain.

Therefore, the present inventors named the novel strain obtained as Lactobacillus acidophilus KNU-02 and deposited it on KCT13233BP, Korea Research Institute of Bioscience and Biotechnology on March 30, 2017.

In one embodiment of the present invention, the microorganism known to give a good effect on livestock immunity from the feces of healthy pigs was isolated and the new strain capable of being used as a livestock immune enhancer was isolated and identified. For the oral administration, And yeast were cultured (see Example 1).

In another embodiment of the present invention, in order to analyze the sugar metabolism characteristics of the novel strain of the present invention, the strain was cultured using various active ingredients, and then the growth of the strain was examined. As a result, it was confirmed that D-fructose, It was confirmed that bios, D-sucrose, D-glucose, D-galactose and D-mannose were used as energy sources (see Example 2).

In another embodiment of the present invention, in order to confirm the livestock immune enhancing effect of the novel strain of the present invention, the effect of increasing the daily gain rate (see Example 3-1), reducing the viremia in the blood (viremia) (See Example 3-2), pulmonary lesion reduction effect (see Example 3-3), and the freeze-dried powder for oral use was prepared using the strain of the present invention, and the survival rate (See Example 4).

Therefore, the novel livestock immune enhancer, oral lyophilized powder preparation and feed additive of the Lactobacillus acidophilus KNU-02 strain of the present invention increases the daily gain rate of pigs and the blood viral concentration viremia), reduces lung lesions, and exhibits immune enhancing effect of livestock, and can be usefully used as a microbial preparation for livestock immune enhancement.

Accordingly, in another aspect of the present invention, the present invention provides a method for producing the Lactobacillus acidophilus KNU-02 strain (Accession No. KCTC13233BP), a culture of the strain, a concentrate of the culture, A lyophilized immune enhancer, an oral lyophilized powder preparation, and a feed additive comprising at least one selected from the group consisting of a combination of these as an active ingredient. More specifically, the animal may be, but is not limited to, a pig or a weaned pig.

As used herein, the term "livestock immune enhancer" means a substance that enhances the normal or decreased immunity of livestock to increase the rearing of livestock, and means to improve bio-defense against microbial infection.

The term "feed additive " as used in the present invention refers to a non-nutrient aid material that is formulated into feeds in small amounts for the purpose of improving the animal health, improving the productivity, improving the meat quality, , Enzymes, organic acids, flavors, antioxidants, various natural substances and functional substances are classified as feed additives.

The Lactobacillus acidophilus strain KNU-02 according to the present invention belongs to a probiotics in feed additives, and is a preparation containing living beneficial microorganisms including fermented products as "probiotics" Means a microbial formulation that inhibits the growth of harmful microorganisms through competitive exclusion with pathogenic microorganisms and helps digestion and absorption of the feed to promote animal growth and improve feed efficiency.

As used herein, the term "viremia" means that the virus exits from the lesion into the bloodstream. Usually, it migrates from the primary lesion to the local lymph node and exits into the bloodstream to cause primary viremia and spread to the whole body. At this stage, clinical symptoms do not appear yet, and blood antibodies work effectively. Thereafter, the virus multiplies in a large number of cells in a specific organ to cause a second viremia. The degree and the duration of the viremia are much larger than those of the first viremia and are directly related to the manifestation of clinical symptoms.

Hereinafter, preferred embodiments of the present invention will be described in order to facilitate understanding of the present invention. However, the following examples are provided only for the purpose of easier understanding of the present invention, and the present invention is not limited by the following examples.

[Example]

Example 1: Lactobacillus acidophilus ( Lactobacillus acidophilus ) Isolation, Identification and Cultivation for Oral Administration of KNU-02 Strain

1-1. Lactobacillus acidophilus ( Lactobacillus acidophilus ) Isolation of KNU-02 strain

In order to isolate the microorganisms which can be used as a livestock immune enhancer, swine flour, which is known to be healthy in breeding pig farms in Mungyeong city, Gyeongbuk province, was collected as a sample. To separate the microorganisms from the swine, 1 g of the swine sample was added to 9 mL of physiological saline solution (0.85% NaCl solution), thoroughly stirred, and diluted stepwise with 9 mL of fresh physiological saline. After dilution, 100 μL was removed from each sample section and spread on nutrient agar. The microorganisms grown as a single colony were classified by the morphological classification method using the colony outline based on the literature information and the microorganisms known to give good effects to the livestock immunity were firstly isolated. The final isolate was selected by confirming the efficacy of the isolated microorganism as a livestock immune enhancer.

1-2. Lactobacillus acidophilus ( Lactobacillus acidophilus ) Identification of KNU-02 strain

In order to identify the strains which can be used as a livestock immune enhancer isolated in Example 1-1, genomic DNA was extracted from the recovered cells (Thompson, 1980), and the separated genomic DNA was used as a template The 16S rRNA gene was amplified by polymerase chain reaction (PCR). The universal primers used were 27F (5'-AGAGTTTGATCCTGGCTCAG-3 ') and 1492R (5'-GGTTACCTTGTTACGACTT-3') respectively (Lane 1991) , Daejeon, Korea). Sequencing to analyze the entire nucleotide sequence of the purified PCR product was performed by Solgent (Daejeon, Korea).

As a result, as shown in Fig. 1, the nucleotide sequence (SEQ ID NO: 1) of the gene (rDNA) encoding 16S rRNA was confirmed.

The nucleotide sequences of the identified strains were compared using BLASTN from National Center for Biotechnology Information (NCBI), and the homology and phylogenetic tree of the nucleotide sequences were determined using the adjacent binding method neighbor-joining methods).

As a result, as shown in FIG. 2, it was confirmed that the isolated strain had a homology of 99% with Lactobacillus acidophilus JCM7711, a previously reported published strain, and 1% , And thus it was recognized as a novel strain belonging to the species of the Acidophilus. This strain was named Lactobacillus acidophilus KNU-02, and the strain was deposited at the BRC (National Institute of Bioscience and Biotechnology) (Accession No. KCTC13233BP).

1-3. Culture of isolates and yeast for oral administration

As a microorganism for oral administration, the final isolated isolate and yeast were used. For Yeast PRRSV capsid protein gene (PRRSV 7) is transformed Pichia Pastoris was used. For the culture of microorganisms, MRS medium and YPD medium were used. 1 L of MRS liquid medium and YPD liquid medium were inoculated with 1% isolate and yeast, respectively, and cultured at 30 ° C. for 24 hours. Cells were recovered by centrifugation and each cell was resuspended in 60 mL of physiological saline. The final 60 mL of cell suspension was used in triplicate, using 20 mL per dose.

Example  2. Lactobacillus Ashford Fillers  ( Lactobacillus acidophilus ) KNU Identification of the sugar metabolism property of -02 strain

In order to confirm the glucose metabolism of the novel Lactobacillus acidophilus strain KNU-02 isolated from Example 1-1, an API 20 NE kit (Bio Merioux) Experiments were conducted according to the experimental method. Using the active ingredients shown in the following Table 1, the strains were cultured in a 30 ° C incubator for 48 hours, and the results were compared using the color change of the API 20 NE kit and the turbidity depending on the growth of the strain.

As a result, as shown in Table 1, the Lactobacillus acidophilus KNU-02 strain of the present invention is a D-fructose, D-cellobiose, D-sucrose, D- Galactose, and D-mannose as an energy source.

Active ingredient result Active ingredient result D-fructose + D-glucose + D-cellobiose + D-ribose - D-arabinose - D-galactose + D-mannose - D-mannitol - D-xylose - D-sorbitol - D-sucrose + D-mannose +

Example  3. Lactobacillus Ashford Fillers  ( Lactobacillus acidophilus ) KNU Measurement of livestock immune effect on -02 strain

3-1. On the weaning money  About Daily growth rate  Increase effect measurement

Three isolates of PRRS-negative pigs from healthy sows were prepared for each group, and weighed and weighed in a separate strain, yeast, saline (mock, Untreated group) were administered three times via an oral feeding tube every two weeks. Two weeks after challenge, PRRSV North American standard virus host JA142 was administered at a concentration of 103 TCID ₅₀ / ml through the nasal cavity. The daily gain rate was determined by calculating the average daily weight gain (ADWG) before and after inoculation of the virus, based on the body weight of the mice before the inoculation and after 2 weeks of the inoculation.

As a result, as shown in FIG. 3, the daily gain rate of the test strain treated with the strain Lactobacillus acidophilus KNU-02 and the test strain treated with yeast and physiological saline before the attack was inoculated As a result, it was confirmed that the strain treated with the strain showed a high daily growth rate and a significant difference from the other experimental groups. In addition, it was confirmed that the daily growth rate of the experimental group treated with the strain KNU-02 was higher than that of the yeast and physiological saline treated groups after the inoculation.

3-2. On the weaning money  Serum viral concentration for viremia ) Reduction effect measurement

Three isolates of PRRS-negative pigs from healthy sows were prepared for isolation of isolate strain, yeast, saline (mock, non-administered group) Were administered three times via an oral feeding tube every two weeks. Two weeks after challenge, PRRSV North American standard virus host JA142 was administered at a concentration of 103 TCID ₅₀ / ml through the nasal cavity. The serum viral concentration was measured every week after the inoculation, and viral RNA was extracted from the serum. Quantitative PCR was performed using the extracted viral RNA. The viral titer (TCID ₅₀ / mL) was calculated based on the number of viral RNA copies in the serum.

As a result, as shown in Fig. 4, when the strain Lactobacillus acidophilus KNU-02 was treated, it was confirmed that the blood virus concentration of the weedy piglets was significantly reduced compared to the other two experimental groups.

3-3. On the weaning money  Measurement of lung lesion reduction effect

Three isolates of PRRS-negative pigs from healthy sows were prepared for each isolate strain, yeast, saline (mock, non-administered group) every 2 weeks For three times via an oral feeding tube. Two weeks after challenge, PRRSV North American standard virus host JA142 was administered at a concentration of 103 TCID ₅₀ / ml through the nasal cavity. To measure the lung lesion, all pigs were euthanized after 2 weeks of inoculation and autopsied and the lungs were removed to evaluate PRRSV - specific lung lesions. Criteria for evaluation of lung lesions were 0: no lesion, 1: weak interstitial pneumonia, 2: moderate interstitial pneumonia, and 3: highly interstitial pneumonia.

As a result, as shown in FIG. 5, when the strain Lactobacillus acidophilus KNU-02 was treated, the lung lesion reduction effect on the weaning pig fell to the level of the weak interstitial lung lesion Respectively.

Example  4. Lactobacillus Ashford Fillers  ( Lactobacillus acidophilus ) KNU -02 strain, and the survival rate was confirmed.

4-1. Lactobacillus Ashford Fillers  ( Lactobacillus acidophilus ) KNU Freeze-dried powder preparation of -02 strain

Lactobacillus acidophilus KNU-02, the final selective isolate, was inoculated into the MRS liquid medium, which was the optimal culture medium, and cultured for 24 hours under optimal conditions. The cultured KNU-02 strain was centrifuged, supernatant was removed, resuspended in physiological saline and centrifuged again to remove the supernatant. After centrifugation, the remaining cells were frozen at -70 ° C for 1 hour and lyophilized for 3 days at 0.051 mbar and -51 ° C using a freeze dryer. The lyophilized powder was obtained by disruption of the lyophilized cells. The weight of the powder was measured by weighing the powder.

As a result, as shown in FIG. 6, Lactobacillus acidophilus strain KNU-02 in powder form prepared by freeze-drying was obtained, and it was confirmed that the weight of the lyophilized powder was 1.42 g.

4-2. Using freeze-dried powder Lactobacillus Ashford Fillers  ( Lactobacillus acidophilus ) KNU -02 survival rate of strains

The lyophilized powder prepared in Example 4-1 was inoculated 1% in MRS liquid medium, which was the optimal medium, and cultured for 24 hours under optimal conditions. Stepwise dilution was carried out using the following culture medium, and 100 μL of each dilution was applied to MRS solid medium. The number of colonies produced in the medium was counted to determine the concentration of the culture in terms of cfu (colony forming unit) per mL. The survival rate was confirmed by calculating the concentration of KNU-02 strain before freeze drying and the concentration of KNU-02 strain cultured using freeze-dried powder.

As a result, as shown in the following Table 2, the microbial growth concentrations before and after freeze-drying were as follows, and the survival rate of about 18% was confirmed using the results.

Microbial growth before and after lyophilization Before lyophilization After lyophilization 1.67 x 10 < ¹¹ > cfu / mL 3.04 × ¹⁰ 10 cfu / mL

It will be understood by those skilled in the art that the foregoing description of the present invention is for illustrative purposes only and that those of ordinary skill in the art can readily understand that various changes and modifications may be made without departing from the spirit or essential characteristics of the present invention. will be. It is therefore to be understood that the above-described embodiments are illustrative in all aspects and not restrictive.

Institution name: Korea Biotechnology Research Institute

Accession number: KCTC13233BP

Checked on: 20170330

<110> Kyungpook National University Industry-Academic Cooperation Foundation <120> Novel Lactobacillus acidophilus KNU-02 having immune enhancing          activity and use thereof <130> MP16-235 <160> 1 <170> KoPatentin 3.0 <210> 1 <211> 1453 <212> DNA <213> Lactobacillus acidophilus <400> 1 gcgtgctaat acatgcaagt cgagcgagct gaaccaacag attcacttcg gtgatgacgt 60 tgggaacgcg agcggcggat gggtgagtaa cacgtgggga acctgcccca tagtctggga 120 taccacttgg aaacaggtgc taataccgga taagaaagca gatcgcatga tcagcttata 180 aaaggcggcg taagctgtcg ctatgggatg gccccgcggt gcattagcta gttggtaggg 240 taacggccta ccaaggcaat gatgcatagc cgagttgaga gactgatcgg ccacattggg 300 actgagacac ggcccaaact cctacgggag gcagcagtag ggaatcttcc acaatggacg 360 aaagtctgat ggagcaacgc cgcgtgagtg aagaaggttt tcggatcgta aagctctgtt 420 gttggtgaag aaggatagag gtagtaactg gcctttattt gacggtaatc aaccagaaag 480 tcacggctaa ctacgtgcca gcagccgcgg taatacgtag gtggcaagcg ttgtccggat 540 ttattgggcg taaagcgagc gcaggcggaa gaataagtct gatgtgaaag ccctcggctt 600 aaccgaggaa ctgcatcgga aactgttttt cttgagtgca gaagaggaga gtggaactcc 660 atgtgtagcg gtggaatgcg tagatatatg gaagaacacc agtggcgaag gcggctctct 720 ggtctgcaac tgacgctgag gctcgaaagc atgggtagcg aacaggatta gataccctgg 780 tagtccatgc cgtaaacgat gagtgctaag tgttgggagg tttccgcctc tcagtgctgc 840 agctaacgca ttaagcactc cgcctgggga gtacgaccgc aaggttgaaa ctcaaaggaa 900 ttgacggggg cccgcacaag cggtggagca tgtggtttaa ttcgaagcaa cgcgaagaac 960 cttaccaggt cttgacatct agtgcaatcc gtagagatac ggagttccct tcggggacac 1020 taagacaggt ggtgcatggc tgtcgtcagc tcgtgtcgtg agatgttggg ttaagtcccg 1080 caacgagcgc aacccttgtc attagttgcc agcattaagt tgggcactct aatgagactg 1140 ccggtgacaa accggaggaa ggtggggatg acgtcaagtc atcatgcccc ttatgacctg 1200 ggctacacac gtgctacaat ggacagtaca acgaggagca agcctgcgaa ggcaagcgaa 1260 tctcttaaag ctgttctcag ttcggactgc agtctgcaac tcgactgcac gaagctggaa 1320 tcgctagtaa tcgcggatca gcacgccgcg gtgaatacgt tcccgggcct tgtacacacc 1380 gcccgtcaca ccatgggagt ctgcaatgcc caaagccggt ggcctaacct tcgggaagga 1440 gccgtctaag cag 1453

Claims (11)

delete delete One or more selected from the group consisting of Lactobacillus acidophilus strain KNU-02 (Accession No. KCTC13233BP), culture of the strain, concentrate of the culture, dried product of the culture, and combinations thereof , Which has the effect of decreasing the PRRSV (Porcine Reproductive and Respiratory Syndrome Virus) concentration (viremia) or the effect of alleviating lung lesions caused by PRRSV (Porcine Reproductive and Respiratory Syndrome Virus).
The method of claim 3,
Wherein the livestock is a pig.
5. The method of claim 4,
Wherein the pig is a progeny animal.
The method of claim 3,
Wherein the animal immunity enhancer increases the daily gain rate.
delete delete delete One or more selected from the group consisting of Lactobacillus acidophilus strain KNU-02 (Accession No. KCTC13233BP), culture of the strain, concentrate of the culture, dried product of the culture, and combinations thereof (PRRSV) (Porcine Reproductive and Respiratory Syndrome Virus) or PRRSV (Porcine Reproductive and Respiratory Syndrome Virus).
The method of claim 3,
The Lactobacillus acidophilus KNU-02 strain (Accession No. KCTC13233BP) comprises a gene (rDNA) base sequence encoding 16S rRNA of SEQ ID NO: 1.

Images